Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus ...Middle East

The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday. Speaking in a briefing, Andrew Pollard, director of the Oxford Vaccine Group, said it is hard to explain the different efficacy rates between the AstraZeneca/Oxford shot and the other vaccines developed by Pfizer and BioNTech and one by Moderna.

Hence then, the article about oxford covid 19 vaccine efficacy would look higher if trial tested for severe virus was published today ( Monday 23/11/2020 - 01:45 PM ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus )

Also on site :

• Shabana Mahmood’s ‘tough and tender’ asylum policy gets the balance right
• Why is Mamdani protecting deadly-reckless e-bike riders?
• The American Revolution is the only one in world history that actually delivered on the promises it made